<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583544</url>
  </required_header>
  <id_info>
    <org_study_id>TC-2216-232-CLP-001</org_study_id>
    <nct_id>NCT00583544</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers</brief_title>
  <acronym>SRD</acronym>
  <official_title>A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous
      system (CNS) neurobiological disorders in anticipation of seeking an indication in depression
      and/or anxiety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hematology, biochemistry, urine analysis, vital sign, ECG, adverse events.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma and urine pharmacokinetics, Pharmaco EEG, Bond-Lader Visual Analogue Scal</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-2216</intervention_name>
    <description>Multiple ascending dose groups will be explored.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects aged 18-40 years old (both ages included).

          2. Subjects must be in good health as determined by their medical history, physical
             examination, psychological examination, ECG, vital signs, standard EEG and laboratory
             tests. A volunteer with a clinical abnormality may be included only if the
             Investigator or his designee considers that the abnormality will not introduce
             additional risk factor for the subject's health, or interfere with the study
             objectives.

          3. Subjects with a body mass index within the range 18-29 kg/m2 and a weight within the
             range of 60-90 kg.

          4. Non-smoker subjects (a cotinine test will be performed at screening and Day -1

          5. Subjects must be able to refrain from consuming xanthine containing beverages, and
             must refrain from intensive physical exercise during the study conduct (until the end
             of study visit).

          6. Subjects must have signed an informed consent form indicating that they understand the
             purpose of and procedures required for the study and are willing to participate in the
             study and comply with the study procedures and restrictions.

          7. Subjects must be affiliated with, or a beneficiary of, a French social security
             system.

        Exclusion Criteria:

        Potential subjects who meet any of the following criteria will be excluded from
        participating in the study:

          1. Any clinically relevant acute or chronic diseases which could interfere with the
             subjects safety during the trial, or expose them to undue risk, or which could
             interfere with the study objectives.

          2. History or presence of gastrointestinal, hepatic, or renal disease or other condition
             known to interfere with the absorption, distribution, metabolism or excretion of
             drugs.

          3. Any history of drug or other significant allergy.

          4. Likely to need any treatment (including dental care) during the study period.

          5. Donation of one or more units of blood within 90 days prior to the screening.

          6. Use of any prescription or over-the-counter medication within 14 days prior to
             admission on Day-1 (not including paracetamol in the range of 1gr/day). In addition
             any medications with central effects are prohibited for a period equal to 5 x
             half-life prior to admission (Day-1), should this period be longer than 14 days.

          7. Alcohol consumption &gt; 40 g alcohol/day (1 glass (25 cl) of beer with 3째 of alcohol =
             7.5 g, or 1 glass (25 cl) of beer with 6째 of alcohol = 15 g, or 1 glass (12.5 cl) of
             wine with 10째 of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42째 of alcohol = 17
             g).

          8. Positive alcotest at screening and Day -1 .

          9. Positive test result on hepatitis B surface antigen, hepatitis C antibody.

         10. Positive test result on HIV 1 and 2 serology.

         11. Excessive daily consumption of xanthines containing drinks (i.e &gt; 500 mg/day of
             caffeine).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Targacept Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>Targacept Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forenap Pharma</name>
      <address>
        <city>Rouffache</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.targacept.com</url>
  </link>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>July 17, 2008</last_update_submitted>
  <last_update_submitted_qc>July 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Geoffrey Dunbar, Vice President, CDRA</name_title>
    <organization>Targacept, Inc</organization>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

